Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an...